Pretreatment characteristics and outcome of the patients (low- and intermediate-risk groups) included in the joint analysis
| Characteristics . | LPA 99 trial, N = 306 . | APL 2000 trial, N = 96 . | P . | Adjusted P* . |
|---|---|---|---|---|
| Age, y, median (Q1-Q3) | 39 (27-50) | 43 (32-51.5) | .15 | — |
| Age younger than 60 y, no. (%) | 281 (91.8) | 94 (97.9) | .036 | — |
| Male sex, no. (%) | 148 (48.4) | 41 (42.7) | .35 | — |
| WBC count, 109/L, median (Q1-Q3) | 1.6 (1.0-3.2) | 1.8 (1.0-3.8) | .73 | — |
| Platelet count, 109/L, median (Q1-Q3) | 23 (13-40) | 36 (20-63) | <.001 | — |
| Fibrinogen level, g/L, median (Q1-Q3) | 1.6 (1.1-2.5) | 1.8 (1.1-2.7) | .58 | — |
| Sanz score, no. (%) | ||||
| Low risk | 73 (23.9) | 43 (44.8) | <.001 | — |
| Intermediate risk | 233 (76.1) | 53 (55.2) | — | — |
| Complete remission, no. (%) | 294 (96.1) | 95 (99.0) | .32 | .28 |
| Deaths in CR, no. (%) | 4/294 (1.4) | 2/95 (2.1) | .38 | .57 |
| Relapses, no. (3-y cumulative incidence, %) | 16/294 (4.2) | 9/95 (14.3) | .03 | .005 |
| Total events, no. (3-y EFS, %) | 31 (91.4) | 12 (89.4) | .16 | .12 |
| Total deaths, no. (3-y OS, %) | 20 (93.8) | 4 (95.6) | .53 | .59 |
| Characteristics . | LPA 99 trial, N = 306 . | APL 2000 trial, N = 96 . | P . | Adjusted P* . |
|---|---|---|---|---|
| Age, y, median (Q1-Q3) | 39 (27-50) | 43 (32-51.5) | .15 | — |
| Age younger than 60 y, no. (%) | 281 (91.8) | 94 (97.9) | .036 | — |
| Male sex, no. (%) | 148 (48.4) | 41 (42.7) | .35 | — |
| WBC count, 109/L, median (Q1-Q3) | 1.6 (1.0-3.2) | 1.8 (1.0-3.8) | .73 | — |
| Platelet count, 109/L, median (Q1-Q3) | 23 (13-40) | 36 (20-63) | <.001 | — |
| Fibrinogen level, g/L, median (Q1-Q3) | 1.6 (1.1-2.5) | 1.8 (1.1-2.7) | .58 | — |
| Sanz score, no. (%) | ||||
| Low risk | 73 (23.9) | 43 (44.8) | <.001 | — |
| Intermediate risk | 233 (76.1) | 53 (55.2) | — | — |
| Complete remission, no. (%) | 294 (96.1) | 95 (99.0) | .32 | .28 |
| Deaths in CR, no. (%) | 4/294 (1.4) | 2/95 (2.1) | .38 | .57 |
| Relapses, no. (3-y cumulative incidence, %) | 16/294 (4.2) | 9/95 (14.3) | .03 | .005 |
| Total events, no. (3-y EFS, %) | 31 (91.4) | 12 (89.4) | .16 | .12 |
| Total deaths, no. (3-y OS, %) | 20 (93.8) | 4 (95.6) | .53 | .59 |
— indicates not applicable.
Adjusted for age, sex, WBC, and platelet count.